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1Background—Patients with obstructive (≥50% stenosis) left main (LM) coronary artery disease (CAD) are at high risk for 
adverse events; prior studies have also documented worse outcomes among women than men with severe multivessel/
LM CAD. However, the prognostic significance of nonobstructive (1%–49% stenosis) LM CAD, including sex-specific 
differences, has not been previously examined.
Methods and Results—In the long-term CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: 
An International Multicenter) registry, patients underwent elective coronary computed tomographic angiography for 
suspected CAD and were followed for 5 years. After excluding those with obstructive LM CAD, 5166 patients were 
categorized as having normal LM or nonobstructive LM (18% of cohort). Cumulative 5-year incidence of death, 
myocardial infarction, or revascularization was higher among patients with nonobstructive LM than normal LM in 
both women and men: women (34.3% versus 15.4%; P<0.0001); men (24.6% versus 18.2%; P<0.0001). A significant 
interaction existed between sex and LM status for the composite outcome (P=0.001). In multivariable Cox regression, 
the presence of nonobstructive LM plaque increased the risk for the composite outcome in women (adjusted hazard 
ratio, 1.48; P=0.005) but not in men (adjusted hazard ratio, 0.98, P=0.806). In subgroup analysis, women with 
nonobstructive LM CAD had a nearly 80% higher risk for events than men with nonobstructive LM CAD (adjusted 
hazard ratio, 1.78; P=0.017); sex-specific interactions were not observed across other patterns (eg, location or extent) 
of nonobstructive plaque.
Conclusion—Nonobstructive LM CAD was frequently detected on coronary computed tomographic angiography 
and strongly associated with adverse events among women. Recognizing the sex-specific prognostic significance of 
nonobstructive LM plaque may augment risk stratification efforts.  (Circ Cardiovasc Imaging. 2017;10:e006246. DOI: 
10.1161/CIRCIMAGING.117.006246.)
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2  Xie et al  Nonobstructive Left Main CAD and Prognosis 
Obstructive left main (LM) coronary artery disease (CAD), defined as ≥50% luminal stenosis, is associated with sig-
nificant morbidity and mortality.1 Although the prevalence 
and burden of obstructive CAD is higher among men, prior 
studies have described worse outcomes among women than 
among men with severe multivessel or LM CAD, including 
after revascularization.2–5 Despite abundant prognostic evi-
dence regarding patients with obstructive LM CAD, clinical 
outcomes of patients with nonobstructive (1%–49% luminal 
stenosis) LM CAD, including sex-specific differences, have 
not been previously evaluated.
See Editorial by Taqueti and Blankstein 
Clinical Perspective
Importantly, nonobstructive CAD is frequently identified 
on coronary angiography among patients with stable ischemic 
heart disease and is more prevalent in symptomatic women 
(≈60%) than in men (≈30%).4,6,7 Furthermore, recent investiga-
tions have described a strong association between nonobstruc-
tive CAD and adverse cardiovascular events in both invasive 
and noninvasive angiographic cohorts; however, comparative 
prognostic data of women versus men with nonobstructive 
CAD are limited.8–14 These findings have prompted increased 
efforts to examine the importance of nonobstructive CAD, 
including characterizing sex-related differences in outcomes, 
as a means to improve prognostic models and more precisely 
identify at-risk patients to target preventive care.7 Notably, 
nonobstructive plaque within the LM has not been an empha-
sis within any of these studies to date.
Accordingly, we sought to determine the prognostic sig-
nificance of nonobstructive LM CAD in a large, real-world 
cohort of patients who underwent elective coronary computed 
tomographic angiography (CCTA) for the evaluation of sus-
pected CAD. Our objectives were to (1) assess the associa-
tion between nonobstructive LM CAD and clinical outcomes, 
including all-cause mortality, nonfatal myocardial infarc-
tion (MI), and coronary revascularization; and (2) determine 
whether sex-specific differences in outcomes exist among 
patients with nonobstructive LM CAD and compared with 
other subgroups of nonobstructive CAD.
Methods
Study Cohort
In the long-term phase of the CONFIRM (Coronary CT Angiography 
Evaluation For Clinical Outcomes: An International Multicenter) reg-
istry, a total of 12 086 stable outpatients underwent elective CCTA 
for evaluation of clinically suspected CAD and had prospective fol-
low-up extended to 5 years. A total of 17 participating sites from 9 
countries enrolled patients between 2002 and 2009. All sites received 
institutional review board approval and oversight, and all patients 
provided informed consent. Patient and site identifiers were not en-
tered into the CONFIRM database. Additional details regarding the 
CONFIRM registry’s design, rationale, site eligibility, and patient re-
cruitment have been previously described.15
The inclusion criteria for our analysis reflected the enrollment in-
dications of the CONFIRM registry, including (1) adults ≥18 years 
of age, (2) referral for CCTA to evaluate for suspected CAD given 
presenting symptoms or for risk stratification using a ≥64-detector 
row scanner, (3) prospective data collection of CAD risk factors and 
CCTA data, and (4) standardized reporting of segmental coronary 
stenosis, as per Society of Cardiovascular Computer Tomography 
guidelines.16,17 Excluded from our study were patients with obstruc-
tive LM CAD or missing LM stenosis severity (n=1147), history of 
known CAD, previous percutaneous coronary intervention, or previ-
ous coronary artery bypass surgery (n=1416), and incomplete adju-
dication of clinical events (n=4357) for a final cohort size of 5166 
patients. All CONFIRM investigators have reviewed and approved 
our study.
Clinical Descriptive Data
All patients enrolled in CONFIRM underwent evaluation by a physi-
cian or nurse prior to CCTA. Each participating site uniformly col-
lected self-reported baseline clinical data, including age, sex, history 
of hypertension, diabetes mellitus, hyperlipidemia, smoking status, 
early family history of early CAD (father <55 or mother <65 years 
of age), left ventricular ejection fraction, and presenting symptom 
characteristics categorized as no chest pain, nonanginal chest pain, 
atypical angina, or typical angina.
CCTA Protocol and Anatomic Definitions
Each CONFIRM site was directed by a level III–trained expert in 
CCTA and followed standardized protocols for performing CCTA 
as defined by guidelines of the Society of Cardiovascular Computer 
Tomography.16,17 The percent luminal stenosis in the LM was coded 
as normal (0% stenosis) or nonobstructive (1%–49% stenosis) by vi-
sual assessment. Luminal stenosis in non-LM vessels, including the 
left anterior descending artery, left circumflex artery, and right coro-
nary artery were also gathered and coded as normal, nonobstructive, 
or obstructive (≥50% stenosis), which were consistent with previous 
CCTA-derived definitions for obstructive and nonobstructive CAD.2 
At all laboratories, intra- and inter-reader reliability were routinely 
assessed and have been previously described in detail.15
Outcome Data Collection and Follow-Up Methods
Our primary outcome was a composite of incident all-cause mortality, 
nonfatal MI, or late coronary revascularization occurring >90 days 
from the index CCTA. Each individual end point was also evaluated 
as a secondary outcome. The National Death Index was queried for 
all-cause death within the United States or determined through direct 
interview with the patient’s family or physician, telephone call, or 
review of medical records for events outside of the United States. MI 
events were confirmed through review of the patient’s medical re-
cords for hospital documentation of biomarker elevation and electro-
cardiographic alterations consistent with the Universal Definition of 
MI.18 Coronary revascularization events were also confirmed through 
review of medical records; however, target vessel revascularization 
was not reported. Only late (>90 days from the index CCTA) revascu-
larization events were used as an end point; earlier revascularization 
events represent continued evaluation of the index but stable CAD 
course for a patient, whereas use of late revascularization is a com-
mon means to separate elective versus nonelective conditions and is 
consistent with prior literature.15 Additional information on ascertain-
ment and adjudication methods have been previously described.15
Statistical Analysis
Using χ2 tests for categorical variables and t tests for normally distrib-
uted or Wilcoxon tests for non-normally distributed continuous vari-
ables, baseline characteristics were compared between patients with 
normal LM and nonobstructive LM. We estimated time to event using 
the Kaplan–Meier method and compared differences in cumulative 
incidence of events between LM groups with log-rank tests.
Next, we tested for an interaction between sex and LM status 
for the study end points and examined sex-specific differences in 
outcomes according to LM status. After meeting the proportional 
hazards assumption by graphical assessment, 4 multivariable Cox 
proportional hazards models were created using covariables defined 
a priori based on clinical judgment. Model 1 included age, hyper-
tension, diabetes mellitus, hyperlipidemia, smoking history, and the 
presence of typical angina to control for baseline demographics, 
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CAD risk factors, and pretest probability for obstructive CAD. Model 
2 included the covariables from model 1 plus the number of non-LM 
coronary vessels with obstructive plaque to adjust for differences in 
obstructive plaque burden between LM strata. As an alternative meth-
od to adjust for co-occurring obstructive plaque, model 3 included the 
covariables from model 1 plus the total number of non-LM coronary 
artery segments with obstructive plaque. Finally, model 4 expanded 
on the previous models with inclusion of the segment involvement 
score (scored 0–15, excluding LM), which accounts for overall CAD 
burden by measuring both nonobstructive and obstructive plaque 
extent.19
We performed several subgroup and sensitivity analyses to test 
the robustness of our findings. (1) We assessed time to event by LM 
status in a subset of 3325 patients without any obstructive CAD to 
further account for baseline differences in plaque burden. (2) In the 
same subset, we examined whether sex-specific differences in risk 
varied based on the location (LM, left anterior descending artery, left 
circumflex artery, or right coronary artery) or extent (per-segment and 
per-vessel) of nonobstructive plaque. (3) To assess for potential selec-
tion bias, the baseline characteristics of patients who were excluded 
(n=6920) were compared with those included in the final cohort. We 
repeated survival analysis on the entire pooled cohort for the end 
point of all-cause mortality, which was the only outcome completely 
adjudicated in CONFIRM. (4) Because target vessel revasculariza-
tion was not known and may have been subject to biases by sex or the 
extent of obstructive CAD, we removed revascularization from the 
composite end point and repeated the survival analysis using death 
or nonfatal MI as the primary outcome. A 2-tailed P value <0.05 was 
considered statistically significant for each analysis. All statistical 
analyses were performed using SAS version 9.4 (Cary, NC).
Results
Clinical and CCTA Characteristics of the Study 
Cohort
Of 5166 patients, 82% had normal LM and 18% had nonob-
structive LM CAD (Table 1). Patients with nonobstructive LM 
were older and had higher baseline rates of CAD risk factors, 
including hypertension, diabetes mellitus, and hyperlipidemia 
(P<0.001). Furthermore, patients with nonobstructive LM 
CAD had more extensive co-occurring obstructive plaque and 
higher segment involvement score (P<0.001). Neither base-
line left ventricular ejection fraction (P=0.232) nor presenting 
symptoms (P=0.424) were significantly different by LM status.
Estimating the Risk of Death, MI, or 
Revascularization
Through a mean 5.3±1.8 years (median 5.5, interquartile range 
5.1–6.2 years) of follow-up, there were 349 deaths, 471 nonfa-
tal MIs, and 364 revascularization events. Cumulative 5-year 
incidence of the composite outcome was 27.3% for patients 
with nonobstructive LM CAD compared with 17.2% for 
patients with normal LM (P<0.0001; Figure 1). Differences in 
the incidence for the individual end points of all-cause mortal-
ity, nonfatal MI, and late coronary revascularization by LM 
status are also displayed.
Table 1. Baseline Characteristics of Study Cohort by Left Main Status
 
All Patients 
(N=5166)
Normal LM 
(N=4241)
Nonobstructive LM 
(N=925) P Value*
Age, y 60±12 60±12 65±10 <0.001
Male 3255 (63) 2592 (61) 663 (71) <0.001
Hypertension 2769 (54) 2230 (53) 539 (59) 0.001
Diabetes mellitus 865 (17) 676 (16) 189 (21) 0.001
Hyperlipidemia 2717 (53) 2128 (50) 589 (64) <0.001
Smoking history 1030 (20) 827 (20) 203 (22) 0.099
Family history of early CAD 1490 (29) 1204 (29) 286 (31) 0.118
LVEF,† % 60±13 60±13 61±15 0.232
Symptom characteristics
  Typical angina 696 (15) 582 (16) 114 (14) 0.424
  Atypical angina 1587 (35) 1295 (35) 292 (35) 0.424
  Noncardiac 409 (9) 341 (9) 68 (8) 0.424
  No chest pain 1867 (41) 1515 (41) 352 (43) 0.424
Extent of obstructive CAD (per vessel)
  1-Vessel 986 (19) 723 (17) 263 (30) <0.001
  2-Vessel 496 (10) 340 (8) 156 (18) <0.001
  3-Vessel 207 (6) 205 (5) 102 (11) <0.001
Extent of obstructive CAD (per segment) 0.8±1.5; 0 [0–1] 0.7±1.4; 0 [0–1] 1.5±1.9; 1 [0–2] <0.001
Overall CAD burden (segment involvement score) 2.6±2.9; 2 [1–6] 1.9±2.4; 2 [0–4] 5.6±2.9; 6 [4–9] <0.001
Values reported as mean±SD (median [interquartile range] also reported if non-normally distributed) or N (%). CAD indicates coronary 
artery disease; LM, left main; and LVEF, left ventricular ejection fraction.
*Comparison of patients with normal LM and nonobstructive LM using χ2 test for categorical variables and t test or Wilcoxon tests for 
continuous variables.
†LVEF only available in 858 (17%) of patients.
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Sex-Specific Differences in Outcomes
Next, we examined sex-specific differences in outcomes 
according to LM status. Women had a lower burden of obstruc-
tive CAD and segment involvement scores than men (P<0.001; 
Table I in the Data Supplement). In both women and men, those 
with nonobstructive LM had a higher incidence of compos-
ite events than those with normal LM: women (34.3% versus 
15.4%; P<0.0001) and men (24.6% versus 18.2%; P<0.0001; 
Figure 2). Importantly, a significant interaction existed between 
sex and LM status for the primary outcome (P=0.001). After 
multivariable adjustment, the association between nonobstruc-
tive LM and the composite end point remained significant in 
women (adjusted hazard ratio, 1.48 [95% confidence interval 
1.21–1.75]; P=0.005) but was not significant in men (adjusted 
hazard ratio, 0.98 [95% confidence interval 0.81–1.18]; 
P=0.806; Tables 2 and 3). Similarly, the association between 
nonobstructive LM and the individual end points of death, 
nonfatal MI, and revascularization also differed by sex and are 
presented in Tables 2 and 3. The sex-specific hazard ratios for 
the composite outcome by other measures of CAD extent are 
displayed in Table II in the Data Supplement.
Subgroup and Sensitivity Analyses
In a subgroup of 3325 patients without any obstructive CAD, 
the cumulative 5-year incidence of the composite outcome 
remained significantly higher among those with nonobstruc-
tive LM than among those with normal LM (18.6% ver-
sus 10.7%; P<0.0001; Figure 3) and was also consistent in 
sex-stratified Kaplan–Meier analysis: women (28.3% versus 
10.5%; P<0.0001); men (14.0% versus 10.8%; P=0.036).
Next, we examined whether sex-related differences in 
outcomes varied by nonobstructive plaque pattern. As shown 
in Figure 4, in subgroups of patients with nonobstructive LM 
CAD, women had a significantly higher risk for adverse events 
than did men (adjusted hazard ratio, 1.78 [1.31–2.25]; P=0.017). 
In contrast, outcomes were not significantly different between 
women and men in other subgroups of nonobstructive plaque.
In addition, we examined the baseline characteristics of 
patients excluded (n=6920) from our analysis (Table III in the 
Data Supplement). In a pooled Kaplan–Meier analysis, those 
with nonobstructive LM CAD had a consistent and elevated 
incidence of death compared with those with normal LM 
(13.9% versus 7.9%; P<0.0001). Similar sex-specific dif-
ferences were also observed: women (18.7% versus 8.1%; 
P<0.0001), men (11.8% versus 7.7%; P<0.0001; Figure I in 
the Data Supplement).
Finally, we removed revascularization events from the com-
posite end point. Consistently, patients with nonobstructive LM 
had higher cumulative incidence of death or MI than patients with 
normal LM (19.8% versus 13.2%; P<0.0001; Figure II in the 
Data Supplement) and when separated by sex: women (26.1% 
versus 13.1%; P<0.0001), men (17.4% versus 13.3%; P=0.001).
Discussion
Although prognosis is well established in the setting of obstruc-
tive LM CAD, our findings were the first to reveal sex-specific 
Figure 1. Cumulative 5-year incidence of events by left main status. Cumulative incidence of the primary composite outcome of all-cause 
mortality, nonfatal myocardial infarction, or coronary revascularization is displayed using a 90-day landmark time. Cumulative events rates 
for the secondary end points of death, nonfatal myocardial infarction, and revascularization are also shown. Patients are stratified as hav-
ing normal LM or nonobstructive LM. LM indicates left main; and Nonobs, nonobstructive.
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differences in long-term outcomes for nonobstructive LM CAD. 
Notably, nonobstructive LM plaque was associated with a nearly 
50% higher risk for adverse events among women independent 
of CAD burden in other vessels, whereas the association between 
nonobstructive LM CAD and future events was not significant 
among men after risk adjustment. Furthermore, women with 
nonobstructive LM plaque had an ≈1.8-fold higher risk for future 
events than men with nonobstructive LM plaque; sex-specific dif-
ferences in outcomes were not observed across other patterns of 
nonobstructive CAD. These findings provide evidence that non-
obstructive LM plaque may represent an important risk marker in 
women that should be considered during risk stratification efforts.
Figure 2. Cumulative 5-year incidence of events by left main status in women and men. Cumulative incidence of the composite outcome 
of all-cause mortality, nonfatal myocardial infarction, or coronary revascularization are displayed by LM status in women and men. LM 
indicates left main; and Nonobs, nonobstructive.
Table 2. Risk of Death, Myocardial Infarction, and Revascularization by Left Main Status in Women
 
Unadjusted Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Composite end point
  Normal LM 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Nonobstructive LM 2.37  
(1.87–3.01)
<0.001
2.02  
(1.57–2.58)
<0.001
1.63  
(1.26–2.10)
<0.001
1.67  
(1.30–2.15)
<0.001
1.48  
(1.21–1.75)
0.005
All-cause mortality
  Normal LM 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Nonobstructive LM 2.52  
(2.31–2.90)
<0.001
1.96  
(1.55–2.36)
0.001
1.87  
(1.45–2.29)
0.003
1.92  
(1.51–2.32)
0.002
1.58  
(1.15-2.2.01)
0.036
Nonfatal MI
  Normal LM 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Nonobstructive LM 1.75  
(1.21–2.52)
0.003
1.60  
(1.10–2.33)
0.015
1.25  
(0.85–1.83)
0.254
1.29  
(0.88–1.89)
0.195
1.22  
(0.81–1.83)
0.334
Revascularization
  Normal LM 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Nonobstructive LM 2.62  
(2.18–3.06)
<0.001
2.33  
(1.87–2.80)
<0.001
1.86  
(1.38–2.34)
0.011
1.94  
(1.47–2.44)
0.006
1.69  
(1.19–2.19)
0.039
Model 1 covariables include age, hypertension, diabetes mellitus, hyperlipidemia, smoking, and angina; Model 2 covariables include those in model 1 plus the number 
of non-LM vessels with obstructive CAD; Model 3 covariables include those in model 1 plus the total number of non-LM segments with obstructive CAD; and Model 4 
covariables include those in model 1 plus the segment involvement score. CI indicates confidence interval; HR, hazard ratio; LM, left main; and MI, myocardial infarction.
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Surprisingly, there has been a paucity of data regarding the 
prognostic implication of nonobstructive LM plaque within the 
published literature. One reason may be that previous studies 
have frequently represented nonobstructive CAD as having a 
uniform level of risk. For instance, in the WISE study (Women’s 
Ischemia Syndrome Evaluation),9 5-year event rates for MI 
were estimated to be 3.9% for patients with any nonobstructive 
CAD. However, the extent and lesion-specific distribution of 
nonobstructive CAD were not further delineated.
More recently, both invasive angiographic and CCTA 
series have characterized gradations of risk based on the extent 
of nonobstructive CAD. Maddox et al12 described 1-year MI 
event rates of 0.24%, 0.56%, and 0.59%, respectively, among 
patients with 1-vessel, 2-vessel, and 3-vessel nonobstructive 
Figure 3. Cumulative 5-year incidence of events among patients without any obstructive CAD. Cumulative incident event rates for the 
composite outcome of all-cause mortality, nonfatal myocardial infarction, or coronary revascularization are displayed among patients 
without any obstructive CAD. Patients are stratified as having normal LM or nonobstructive LM. Cumulative incidence curves are also dis-
played in women and men, separately. CAD indicates coronary artery disease; LM, left main; and Nonobs, nonobstructive.
Table 3. Risk of Death, Myocardial Infarction, and Revascularization by Left Main Status in Men
 
Unadjusted Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Composite end point
  Normal LM 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Nonobstructive LM 1.44  
(1.21–1.71)
<0.001
1.18  
(0.99–1.42)
0.065
0.99  
(0.82–1.19)
0.879
1.07  
(0.90–1.29)
0.438
0.98  
(0.81–1.18)
0.806
All-cause mortality
  Normal LM 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Nonobstructive LM 1.57  
(1.16–2.12)
0.004
1.14  
(0.84–1.55)
0.412
1.04  
(0.75–1.44)
0.817
1.13  
(0.83–1.54)
0.448
0.98  
(0.70–1.36)
0.894
Nonfatal MI
  Normal LM 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Nonobstructive LM 1.32  
(1.01–1.72)
0.041
1.20  
(0.91–1.58)
0.203
0.98  
(0.74–1.30)
0.887
1.06  
(0.80–1.41)
0.677
1.02  
(0.76–1.37)
0.909
Revascularization
  Normal LM 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Nonobstructive LM 1.46  
(1.11–1.91)
0.007
1.18  
(0.89–1.57)
0.232
0.98  
(0.73–1.31)
0.888
1.05  
(0.79–1.40)
0.743
0.94  
(0.69–1.27)
0.682
Model 1 covariables include age, hypertension, diabetes mellitus, hyperlipidemia, smoking, and angina; Model 2 covariables include those in model 1 plus the number 
of non-LM vessels with obstructive CAD; Model 3 covariables include those in model 1 plus the total number of non-LM segments with obstructive CAD; and Model 4 
covariables include those in model 1 plus the segment involvement score. CI indicates confidence interval; HR, hazard ratio; LM, left main; and MI, myocardial infarction.
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CAD (defined as 20%–49% stenosis on invasive angiography). 
Similar proportional increases in mortality rates were reported 
with increasing nonobstructive vessel involvement in CCTA 
cohorts.20 In contrast to our study, these prior investigations 
had shorter follow-up times, and nonobstructive LM plaque 
was classified as 1-vessel nonobstructive CAD, as a lesion 
within the left anterior descending artery territory, or incorpo-
rated within the segment involvement score.2,3,8,10,20 One excep-
tion was a small, single-center CCTA study of 76 patients with 
nonobstructive LM CAD, of whom, none experienced an event 
after 20 months of follow-up.21 Thus, our investigation expands 
on previous findings with longer, 5-year follow-up, and to our 
knowledge, this is the first study sufficiently powered to assess 
the prognostic significance of nonobstructive LM CAD.
Specifically, our study revealed that nonobstructive LM 
plaque was strongly associated with adverse events in women 
but not in men, independent of CAD burden in other vessels. 
These sex-specific differences in prognosis were not observed 
for other subgroups of patients with multisegment or multivessel 
nonobstructive CAD. Our results are in concordance with prior 
studies by Leipsic and others, who did not find that outcomes in 
women versus men differed based on the extent of nonobstruc-
tive CAD; however, disparities in prognosis based on the loca-
tion of nonobstructive plaque (eg, LM versus other vessel) were 
not previously explored.11,14 Shaw et al2–4 described both higher 
in-hospital and 4-year mortality among women with significant 
atherosclerotic burden or high-risk lesions, such as obstructive 
multivessel or LM CAD as compared with men; we now extend 
these observations of sex-based differences in outcomes of LM 
disease to patients with nonobstructive plaque.
Although elucidating possible mechanisms for the associa-
tion between nonobstructive LM plaque and adverse outcomes 
in women requires additional investigation, several potential 
explanations exist. Independent of body surface area, women 
are known to have significantly smaller coronary arterial sizes 
than men, including the luminal area of the LM, which has 
been associated with worse outcomes in women than men after 
coronary revascularization and may also increase susceptibility 
to thrombotic occlusion.22 Numerous pathology examinations 
and intravascular ultrasound studies have also characterized 
differences in coronary atherosclerotic composition and pro-
gression between women and men.23,24 Although women have 
been noted to have less severe and extensive CAD than men, 
positive coronary artery remodeling was detected in the major-
ity (73%) of women without obstructive CAD in an intravas-
cular ultrasound substudy of WISE.24 These nonobstructive 
but positively remodeled plaques have been proposed to serve 
as precursor lesions vulnerable to future erosion or rupture.25 
Given that the LM subtends a large proportion of the myocar-
dium, any sex-related differences in plaque vulnerability in 
the LM could conceivably place women at a significant and 
higher risk for downstream coronary events; additional char-
acterization of LM plaque morphology is needed to improve 
discrimination of at-risk lesions. Moreover, previous studies 
from the National Cardiovascular Data Registry have shown 
that patients with nonobstructive CAD are less than half as 
likely to receive aspirin, statins, or β-blockers as compared 
with patients with obstructive CAD.26–28 The preponderance of 
hidden or positively remodeled plaque in women may also lead 
to an underestimation of true atherosclerotic burden and fur-
ther therapeutic delay, potentially contributing to disparities in 
outcomes between women and men with nonobstructive CAD.
Our findings add to the growing body of evidence that 
depict a heterogeneous distribution of risk among patients 
with nonobstructive CAD; both the extent and location of non-
obstructive plaque seem to confer varying prognostic value. 
Importantly, estimated rates of obstructive CAD on elective 
cardiac catheterization have been as low as ≈40%, with a 
disproportionately lower yield for obstructive CAD among 
women compared with men.6,29 Guideline recommendations 
on the management of this large cohort of patients with non-
obstructive CAD have remained poorly defined; however, 
simple reassurance and complacency in clinical management 
are not likely appropriate given the prognostic implications of 
nonobstructive plaque. In this context, elucidating and recog-
nizing high-risk patterns of nonobstructive CAD, such as the 
sex-specific significance of nonobstructive LM plaque, may 
not only help provide a more granular estimation of cardio-
vascular risk but may also identify promising targets to focus 
preventive care as higher risk patients may derive a greater 
benefit from risk-modifying therapies. Future prospective ran-
domized trials are still needed to determine optimal strategies 
for therapeutic risk reduction among patients with nonob-
structive CAD.
Figure 4. Sex-specific differences in risk 
by nonobstructive plaque location and 
extent. Risk-adjusted hazard ratios com-
paring women to men for the composite 
outcome of all-cause mortality, nonfatal 
myocardial infarction, or revasculariza-
tion are shown in different subgroups of 
nonobstructive CAD. All models adjusted 
for age, hypertension, hyperlipidemia, 
diabetes mellitus, smoking, and angina. 
CAD indicates coronary artery disease; 
CI, confidence interval; LAD, left anterior 
descending artery; LCX, left circumflex 
artery; LM, left main; MI, myocardial 
infarction; and RCA, right coronary artery.
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Study Limitations
Inherently, we were unable to account for all confounders 
given our retrospective study design; however, we used several 
multivariable regression models that incorporated all avail-
able and pertinent clinical characteristics. Selection bias may 
have also impacted our analysis because we excluded many 
higher risk patients with obstructive LM or a history of CAD; 
however, after pooling all patients, those with nonobstructive 
LM remained at higher risk of death than those with normal 
LM, and similar sex-specific differences in outcomes were 
observed. Nonetheless, both external and prospective valida-
tion of our results remains to be performed, but we chose the 
CONFIRM registry for our initial analysis because it repre-
sents the largest CCTA cohort and with the longest duration of 
patient follow-up. Moreover, we did not have further details 
on plaque vulnerability, which may have yielded additional 
sex-specific predictive information and should be included 
in future prognostic models derived from invasive (eg, intra-
vascular ultrasound or optical coherence tomography) or 
noninvasive imaging cohorts. Similarly, both left ventricular 
ejection fraction and myocardial ischemia carry important 
prognostic value and may have influenced downstream clini-
cal outcomes; however, neither were core variables defined 
by CONFIRM and were, thus, not consistently documented 
by all enrolling sites. Finally, the CONFIRM registry did not 
collect information regarding medication use or post-CCTA 
changes in clinical management, which may have differed by 
sex and impacted patient outcomes.
Conclusion
Although abundant prognostic data have documented poor 
clinical outcomes among patients with obstructive LM CAD, 
our findings were the first to reveal an elevated 5-year risk for 
death, MI, or revascularization associated with nonobstruc-
tive LM CAD. Specifically, nonobstructive LM plaque may 
represent an important risk marker in women, potentially 
contributing to disparities in outcomes between women and 
men with nonobstructive CAD. Recognizing the sex-specific 
prognostic significance of nonobstructive LM plaque may 
improve future risk stratification efforts in patients undergo-
ing evaluation for CAD.
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CLINICAL PERSPECTIVE
Although it is well established that obstructive left main (LM) coronary artery disease has major prognostic implications, our 
study reveals that nonobstructive LM plaque is also associated with adverse cardiovascular events. Importantly, the presence 
of nonobstructive LM coronary artery disease was associated with a nearly 50% increase in risk for future events in women, 
independent of coronary artery disease burden or extent in other vessels; however, the association between nonobstructive LM 
plaque and clinical outcomes was not significant in men. These findings show the heterogeneous profile of risk that exists for 
nonobstructive coronary artery disease because both plaque extent and location carry different prognostic value in women and 
men. Future risk stratification efforts should recognize nonobstructive LM plaque in women as an important marker of risk.
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SUPPLEMENTAL MATERIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 1. Baseline Characteristics of Study Cohort by Gender 
  
All Women 
(N=1,911) 
All Men 
(N=3,255) 
P- Value* 
Women with 
Nonobstructive LM 
(N=261) 
Men with 
Nonobstructive LM 
(N=663) 
P-Value** 
Age, years 62±11 59±12 <0.001 67±10 63±10 <0.001 
Hypertension  1,135 (60) 1,634 (50) <0.001 185 (71) 354 (54) <0.001 
Diabetes  329 (17) 536 (16) 0.474 57 (22) 132 (20) 0.516 
Hyperlipidemia  1,033 (54) 1,683 (52) 0.095 170 (65) 418 (63) 0.578 
Smoking History 263 (14) 767 (24) <0.001 53 (20) 150 (23) 0.434 
Family History of 
Early CAD 
602 (32) 887 (28) 0.001 87 (34) 198 (30) 0.288 
Symptom 
Characteristics   
<0.001 
  
0.003 
   Typical angina  282 (17) 414 (14)  43 (18) 71 (12)  
   Atypical angina 646 (38) 941 (33)  93 (40) 199 (34)  
   Non-cardiac  188 (11) 221 (8)  21 (9) 47 (8)  
   No chest pain  571 (34) 1,295 (45)  77 (33) 274 (46)  
Extent of Obstructive 
CAD (per-Vessel) 
  <0.001 
  
0.046 
   1-vessel 291 (16) 695 (22)  73 (29) 190 (30)  
   2-vessel 115 (6) 381 (12)  37 (15) 119 (19)  
   3-vessel 74 (4) 232 (7)  21 (8) 80 (13)  
Extent of Obstructive 
CAD (per-Segment) 
0.6±1.2;         
0 [0-1] 
1.0±0.9;           
0 [0-1] 
<0.001 
1.2±1.7; 
1 [0-2] 
1.6±1.9; 
1 [0-2] 
0.008 
Overall CAD Burden 
(Segment 
Involvement Score) 
1.9±1.8; 
2 [0-4] 
2.9±2.8; 
3 [1-6] 
<0.001 
5.3±2.9; 
5 [3-8] 
5.8±2.9;                           
7 [4-9] 
0.004 
 
 
Values reported as mean ± standard deviation (median [interquartile range] also reported  
if non-normally distributed), or N (%) 
*Comparison of women and men using  
chi-squared test for categorical variables and t-test or Wilcoxon tests for continuous variables 
**Comparison of women with nonobstructive LM CAD and men with nonobstructive  
LM CAD using chi-squared test for categorical variables and t-test or Wilcoxon tests  
for continuous variables 
CAD: Coronary artery disease; LM: Left main; LVEF: Left ventricular ejection fraction;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CAD: Coronary artery disease; CI: Confidence Interval; HR: Hazard ratio 
 
 
 
 
 
 
 
 
 
Supplemental Table 2. Sex-Specific Hazard Ratios for the Composite Outcome by CAD Extent  
  Women  Men 
  Univariable HR (95% CI) P-Value  Univariable HR (95% CI) P-Value 
No CAD 1.00 Ref 
 
1.00 Ref 
Nonobstructive CAD      
1-Vessel 
Nonobstructive 
2.01 (1.41-2.86) 
<0.001  
1.82 (1.30-2.53) 
<0.001 
2-Vessel 
Nonobstructive 
2.95 (1.93-4.53) 
<0.001  
2.56 (1.82-3.63) 
<0.001 
3-Vessel 
Nonobstructive 
3.58 (2.31-5.55) 
<0.001  
3.02 (2.05-4.45) 
<0.001 
Obstructive CAD      
1-Vessel Obstructive 5.26 (3.91-7.09) <0.001 
 5.04 (3.87-6.58) <0.001 
2-Vessel Obstructive 5.85 (4.00-8.56) <0.001 
 5.09 (3.79-6.83) <0.001 
3-Vessel Obstructive 8.10 (5.38-12.20) <0.001 
 7.13 (5.24-9.72) <0.001 
Segment Involvement 
Score      
1-3 Segments 2.28 (1.67-3.11) <0.001  2.21 (1.66-2.93) <0.001 
4-9 Segments 3.78 (2.78-5.13) <0.001  3.20 (2.42-4.22) <0.001 
>=10 Segments 4.37 (2.69-7.10) <0.001  4.08 (2.90-5.73) <0.001 
  
Supplemental Table 3. Baseline Characteristics of Included versus Excluded Patients  
  
Included 
(n=5,166) 
Excluded 
(n=6,920) 
P- Value* 
Age, years 61±12 57±14 <0.001 
Male 3255 (63) 3,813 (55) <0.001 
Hypertension  2769 (54) 4,054 (59) <0.001 
Diabetes  865 (17) 1,319 (19) 0.001 
Hyperlipidemia  2717 (53) 4,125 (60) <0.001 
Smoking History 1030 (20) 1,816 (26) <0.001 
Family History of Early CAD 1,490 (29) 3,101 (45) <0.001 
Symptom Characteristics 
  
<0.001 
   Typical angina  696 (15) 1,375 (24)  
   Atypical angina 1,587 (35) 1,642 (28)  
   Non-cardiac 409 (9) 1,286 (22)  
   No chest pain  1,867 (41) 1,538 (26)  
LM Stenosis Severity   <0.001 
   Normal LM 4,241 (82) 5,145 (83)  
   Nonobstructive LM 925 (18) 628 (10)  
   Obstructive LM 0 (0) 426 (7)  
Extent of Obstructive CAD (per-vessel)   <0.001 
   1-vessel 986 (19) 1,290 (21)  
   2-vessel 496 (10) 870 (14)  
   3-vessel 307 (6) 753 (12)  
Extent of Obstructive CAD (per-segment) 0.8±1.5;       1.2±1.9;      <0.001 
 0 [0-1]  0 [0-2] 
Overall CAD Burden (Segment Involvement 
Score) 
2.6±2.9;      
2 [1-6] 
2.6±2.6;                
3 [1-6] 
<0.001 
 
 
Values reported as mean ± standard deviation deviation 
(median [interquartile range] also reported if non-normally 
distributed), or N (%) 
  
*Comparison of included and excluded patients using  
chi-squared test for categorical variables and t-test or Wilcoxon tests for continuous  
variables 
CAD: Coronary artery disease; LM: Left main; LVEF: Left ventricular ejection fraction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplemental Figure Legends 
 
Supplemental Figure 1. Cumulative 5-Year Incidence of Death Including All Patients  
Cumulative incidence of all-cause mortality in a pooled cohort that includes all previously 
excluded patients. Patients are stratified as having normal LM or nonobstructive LM.  
Cumulative incidence curves are also displayed in women and men, separately. 
CAD: Coronary artery disease; LM: Left main; Nonobs: Nonobstructive 
 
Supplemental Figure 2. Cumulative 5-Year Incidence of Death or MI  
Cumulative incidence of death or MI as the composite endpoint. Patients are stratified as having 
normal LM or nonobstructive LM.  
Cumulative incidence curves are also displayed in women and men, separately. 
Cumulative incidence curves are also displayed in women and men, separately. 
CAD: Coronary artery disease; LM: Left main; MI: Myocardial infarction; Nonobs: 
Nonobstructive 
 
 
 
 
 
 
 
 
 
 
 
 
